Docosahexaenoic acid, G protein-coupled receptors, and melanoma: is G protein-coupled receptor 40 a potential therapeutic target?

PubWeight™: 0.77‹?›

🔗 View Article (PMC 4057893)

Published in J Surg Res on January 29, 2014

Authors

Deepika Nehra1, Amy H Pan2, Hau D Le1, Erica M Fallon1, Sarah J Carlson1, Brian T Kalish1, Mark Puder3

Author Affiliations

1: Department of Surgery and the Vascular Biology Program, Children's Hospital Boston, Boston, Massachusetts; Department of Surgery, Harvard Medical School, Boston, Massachusetts.
2: Department of Surgery and the Vascular Biology Program, Children's Hospital Boston, Boston, Massachusetts.
3: Department of Surgery and the Vascular Biology Program, Children's Hospital Boston, Boston, Massachusetts; Department of Surgery, Harvard Medical School, Boston, Massachusetts. Electronic address: mark.puder@childrens.harvard.edu.

Articles cited by this

A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem (1957) 173.99

Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer (2010) 10.61

GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell (2010) 8.69

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54

Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature (2003) 6.87

Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol (2004) 5.49

Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr (2002) 4.40

Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr (1991) 4.09

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet (2012) 3.46

Paleolithic nutrition. A consideration of its nature and current implications. N Engl J Med (1985) 3.29

Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol (2006) 2.62

Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother (2006) 2.47

Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis (1999) 2.08

Importance of the ratio of omega-6/omega-3 essential fatty acids: evolutionary aspects. World Rev Nutr Diet (2003) 1.98

Diet and risk of cutaneous malignant melanoma: a prospective study of 50,757 Norwegian men and women. Int J Cancer (1997) 1.52

Melanoma growth is reduced in fat-1 transgenic mice: impact of omega-6/omega-3 essential fatty acids. Proc Natl Acad Sci U S A (2006) 1.42

Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res (2001) 1.35

Case-control study of malignant melanoma in Washington State. II. Diet, alcohol, and obesity. Am J Epidemiol (1994) 1.28

TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther (2011) 1.19

Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care (2012) 1.10

Importance of the omega-6/omega-3 balance in health and disease: evolutionary aspects of diet. World Rev Nutr Diet (2011) 1.08

A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther (2012) 1.02

Mediterranean-inspired diet lowers the ratio of serum phospholipid n-6 to n-3 fatty acids, the number of leukocytes and platelets, and vascular endothelial growth factor in healthy subjects. Am J Clin Nutr (2006) 1.01

Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: association with decreased pRb phosphorylation. Cancer Res (2000) 1.01

Advances in systemic treatment of melanoma. Ann Oncol (2010) 1.01

Evolutionary aspects of the dietary omega-6:omega-3 fatty acid ratio: medical implications. World Rev Nutr Diet (2009) 0.98

Novel therapeutics for melanoma. Expert Rev Anticancer Ther (2009) 0.96

Role of omega-3 polyunsaturated fatty acids on cyclooxygenase-2 metabolism in brain-metastatic melanoma. J Lipid Res (2005) 0.93

Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells. Biomed Pharmacother (2005) 0.92

Antineoplastic effects of n-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies. Nutr Cancer (2009) 0.90

Immunomodulatory cytokines as therapeutic agents for melanoma. Immunotherapy (2011) 0.88

Docosahexaenoic acid and arachidonic acid prevent essential fatty acid deficiency and hepatic steatosis. JPEN J Parenter Enteral Nutr (2011) 0.85

Trans-fatty-acid content of common foods. N Engl J Med (1993) 0.84

Melanoma and dietary lipids. Nutr Cancer (1987) 0.83

NSAIDs in dermatologic therapy: review and preview. J Cutan Med Surg (2002) 0.83

N-3 polyunsaturated fatty acids accentuate B16 melanoma growth and metastasis through suppression of tumoricidal function of T cells and macrophages. Anticancer Res (2000) 0.80

An enhanced apoptosis and a reduced angiogenesis are associated with the inhibition of lung colonisation in animals fed an n-3 polyunsaturated fatty acid-rich diet injected with a highly metastatic murine melanoma line. Br J Nutr (2008) 0.77

Nutrition and melanoma. Int J Dermatol (1984) 0.77